384
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      suPARnostic ® as a treatment efficacy monitoring tool in systemic inflammatory response syndrome/sepsis patients

      abstract
      1 , 1 , 1 , 1 , 1
      Critical Care
      BioMed Central
      Sepsis 2008
      19-22 November 2008

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background Biomarkers may aid in risk triaging of systemic inflammatory response syndrome (SIRS) patients at admittance to hospital and in the monitoring of response to medical intervention. The overall aim is reducing mortality in SIRS and sepsis patients. Methods A prospectively collected cohort of patients with SIRS that were admitted to an emergency department and a department of infectious diseases at a Copenhagen University hospital were studied. Samples obtained daily during hospitalization were measured for soluble urokinase plasminogen activator receptor (suPAR) using the CE/IVD-approved (the product complies with the European Directives for In-Vitro Diagnostics) suPARnostic® assay and were compared with various other clinical parameters associated with assessing disease severity, including C-reactive protein, procalcitonin, Simplified Acute Physiology Score II, and Sepsis-related Organ Failure Assessment scores. Survival was assessed using receiver operating curve statistics. Results One hundred and fifty-one patients were included in the study, nine of whom died within 30 days of admission. Admission levels of suPAR were higher among non-survivors compared to survivors with an area under the curve of 0.80 and 0.92 when combined with age. Admission levels of procalcitonin and C-reactive protein were not significantly different between survivors and nonsurvivors. Simplified Acute Physiology Score II and Sepsis-related Organ Failure Assessment scores were significant predictors of death in this setting as well. During treatment, survivors showed overall declining suPAR levels (Figure 1) while continuously elevated suPAR levels were observed in nonsurvivors (Figure 2). Figure 1 suPAR levels among surviving SIRS patients during treatment. Dotted line, mean suPAR among patients with an inclusion suPAR >5 ng/ml (n = 50). Dashed line, suPAR levels among patients with an inclusion suPAR <5 ng/ml (n = 68). Figure 2 suPAR levels among patients who either had severe complications (n = 14) or died (n = 9) within 30 days of hospitalization. Dotted line, mean suPAR for the 23 patients. Conclusion The suPARnostic® assay provided significant information on risk of mortality following admission. Continuous elevated suPAR levels during treatment were associated with poor clinical outcome.

          Related collections

          Author and article information

          Conference
          Crit Care
          Critical Care
          BioMed Central
          1364-8535
          1466-609X
          2008
          18 November 2008
          : 12
          : Suppl 5
          : P37
          Affiliations
          [1 ]Copenhagen University Hospital Hvidovre, Clinical Research Unit, Hvidovre, Denmark
          Article
          cc7070
          10.1186/cc7070
          3300629
          292678bb-88ce-4a6d-822a-7b9534bcfc66
          Copyright ©2008 Eugen-Olsen et al; licensee BioMed Central Ltd.
          Sepsis 2008
          Granada, Spain
          19-22 November 2008
          History
          Categories
          Poster Presentation

          Emergency medicine & Trauma
          Emergency medicine & Trauma

          Comments

          Comment on this article